Research programme: obesity therapies - Sorrento Therapeutics
Latest Information Update: 07 Nov 2013
At a glance
- Originator Sorrento Therapeutics
- Class Antibodies; Vaccines
- Mechanism of Action Ghrelin antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity
Most Recent Events
- 05 Nov 2013 Early research in Obesity in USA (Parenteral)